- Home
- CTVA vs EW Comparison
CTVA vs EW Comparison
Compare CTVA & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTVA
- EW
- Stock Information
- Founded
- CTVA 2018
- EW 1958
- Country
- CTVA United States
- EW United States
- Employees
- CTVA N/A
- EW N/A
- Industry
- CTVA Farming/Seeds/Milling
- EW Industrial Specialties
- Sector
- CTVA Consumer Staples
- EW Health Care
- Exchange
- CTVA Nasdaq
- EW Nasdaq
- Market Cap
- CTVA 44.9B
- EW 42.1B
- IPO Year
- CTVA N/A
- EW 2000
- Fundamental
- Price
- CTVA $63.97
- EW $72.01
- Analyst Decision
- CTVA Strong Buy
- EW Buy
- Analyst Count
- CTVA 16
- EW 21
- Target Price
- CTVA $68.06
- EW $79.95
- AVG Volume (30 Days)
- CTVA 3.4M
- EW 4.4M
- Earning Date
- CTVA 05-07-2025
- EW 04-24-2025
- Dividend Yield
- CTVA 1.07%
- EW N/A
- EPS Growth
- CTVA 26.57
- EW 202.39
- EPS
- CTVA 1.30
- EW 6.97
- Revenue
- CTVA $16,908,000,000.00
- EW $5,439,500,000.00
- Revenue This Year
- CTVA $4.27
- EW $10.16
- Revenue Next Year
- CTVA $3.44
- EW $9.73
- P/E Ratio
- CTVA $48.96
- EW $10.30
- Revenue Growth
- CTVA N/A
- EW 8.57
- 52 Week Low
- CTVA $50.01
- EW $58.93
- 52 Week High
- CTVA $66.24
- EW $95.25
- Technical
- Relative Strength Index (RSI)
- CTVA 60.55
- EW 54.80
- Support Level
- CTVA $60.72
- EW $70.33
- Resistance Level
- CTVA $63.13
- EW $72.74
- Average True Range (ATR)
- CTVA 1.22
- EW 1.51
- MACD
- CTVA 0.32
- EW 0.27
- Stochastic Oscillator
- CTVA 98.86
- EW 85.28
About CTVA Corteva Inc.
Corteva is an agricultural inputs pure play that was formed in 2019 when it was spun off from DowDuPont. The company is a leader in the development of new seed and crop protection products. Seeds generate the majority of profits with the remainder coming from crop protection products. Corteva operates globally, but around half of revenue comes from North America.
About EW Edwards Lifesciences Corporation
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.